While both studies highlight the predictive value of Ki-67 and p53, our meta-analysis emphasises the clinical significance of drug-resistant proteins in TNBC therapy, whereas Faur and colleagues focus more on lipid profiles and tumour characteristics across various breast cancer subtypes. This evidence concerns the gene TP53 and breast cancer.